CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the following conferences:
